1. Home
  2. BHST vs KZIA Comparison

BHST vs KZIA Comparison

Compare BHST & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioHarvest Sciences Inc.

BHST

BioHarvest Sciences Inc.

HOLD

Current Price

$4.28

Market Cap

104.2M

Sector

N/A

ML Signal

HOLD

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$7.34

Market Cap

93.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHST
KZIA
Founded
2007
1994
Country
Canada
Australia
Employees
87
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
104.2M
93.2M
IPO Year
N/A
2002

Fundamental Metrics

Financial Performance
Metric
BHST
KZIA
Price
$4.28
$7.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$12.00
$17.67
AVG Volume (30 Days)
17.5K
113.5K
Earning Date
05-14-2026
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$146.27
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.10
$0.64
52 Week High
$12.80
$17.40

Technical Indicators

Market Signals
Indicator
BHST
KZIA
Relative Strength Index (RSI) 48.42 47.82
Support Level $4.19 $6.44
Resistance Level $4.96 $8.05
Average True Range (ATR) 0.21 0.69
MACD 0.03 -0.08
Stochastic Oscillator 33.33 26.63

Price Performance

Historical Comparison
BHST
KZIA

About BHST BioHarvest Sciences Inc.

BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: